Literature DB >> 479903

Plasma and cerebrospinal fluid tryptophan in multiple sclerosis and degenerative diseases.

F Monaco, S Fumero, A Mondino, R Mutani.   

Abstract

Tryptophan and competing neutral amino acid levels were found to be diminished in the plasma of patients with multiple sclerosis and degenerative diseases, the greatest decrease being of tryptophan. Cerebrospinal fluid tryptophan was decreased in multiple sclerosis and motor neurone disease, while leucine and valine were increased. These changes might lead to decreased synthesis of brain serotonin and brain proteins. The ratio between neutral amino acids and tryptophan might be used as an ancillary test in the screening of degenerative diseases.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 479903      PMCID： PMC490278          DOI： 10.1136/jnnp.42.7.640

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  7 in total

1.  A new approach for obtaining total tryptophan recovery in plasma samples deproteinized with sulphosalicylic acid.

Authors:  A Mondino; G Bongiovanni; S Fumero
Journal:  J Chromatogr       Date:  1975-02-12

2.  Free amino acids in serum of patients with epilepsy: significant increase in taurine.

Authors:  F Monaco; R Mutani; L Durelli; M Delsedime
Journal:  Epilepsia       Date:  1975-06       Impact factor: 5.864

3.  [Amino acid determinations in the serum of patients with multiple sclerosis (author's transl)].

Authors:  W Kisser
Journal:  Wien Klin Wochenschr       Date:  1974-02-08       Impact factor: 1.704

4.  Free amino acids in the cerebrospinal fluid of epileptic subjects.

Authors:  R Mutani; F Monaco; L Durelli; M Delsedime
Journal:  Epilepsia       Date:  1974-12       Impact factor: 5.864

5.  Brain serotonin content: physiological regulation by plasma neutral amino acids.

Authors:  J D Fernstrom; R J Wurtman
Journal:  Science       Date:  1972-10-27       Impact factor: 47.728

6.  Automatic ion-exchange chromatography of amino acids. Experimental studies for optimising resin column dimensions.

Authors:  A Mondino
Journal:  J Chromatogr       Date:  1970-07-29

7.  Effect of phenylalanine on protein synthesis in the developing rat brain.

Authors:  H C Agrawal; A H Bone; A N Davison
Journal:  Biochem J       Date:  1970-04       Impact factor: 3.857
  7 in total
  35 in total

1.  Simultaneous analysis of plasma and CSF by NMR and hierarchical models fusion.

Authors:  Agnieszka Smolinska; Joram M Posma; Lionel Blanchet; Kirsten A M Ampt; Amos Attali; Tinka Tuinstra; Theo Luider; Marek Doskocz; Paul J Michiels; Frederic C Girard; Lutgarde M C Buydens; Sybren S Wijmenga
Journal:  Anal Bioanal Chem       Date:  2012-03-07       Impact factor: 4.142

2.  Clinical relevance of circadian melatonin release in relapsing-remitting multiple sclerosis.

Authors:  Simone Kern; Michael Geiger; Madlen Paucke; Alina Kästner; Katja Akgün; Tjalf Ziemssen
Journal:  J Mol Med (Berl)       Date:  2019-08-30       Impact factor: 4.599

Review 3.  Kynurenines in the CNS: recent advances and new questions.

Authors:  László Vécsei; Levente Szalárdy; Ferenc Fülöp; József Toldi
Journal:  Nat Rev Drug Discov       Date:  2012-12-14       Impact factor: 84.694

4.  Targeted metabolomics approach for identification of relapsing-remitting multiple sclerosis markers and evaluation of diagnostic models.

Authors:  Marat F Kasakin; Artem D Rogachev; Elena V Predtechenskaya; Vladimir J Zaigraev; Vladimir V Koval; Andrey G Pokrovsky
Journal:  Medchemcomm       Date:  2019-08-12       Impact factor: 3.597

5.  Assessing the Metabolomic Profile of Multiple Sclerosis Patients Treated with Interferon Beta 1a by 1H-NMR Spectroscopy.

Authors:  Lorena Lorefice; Federica Murgia; Giuseppe Fenu; Jessica Frau; Giancarlo Coghe; Maria Rita Murru; Stefania Tranquilli; Andrea Visconti; Maria Giovanna Marrosu; Luigi Atzori; Eleonora Cocco
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

Review 6.  The role of kynurenines in the pathomechanism of amyotrophic lateral sclerosis and multiple sclerosis: therapeutic implications.

Authors:  Judit Füvesi; Cecilia Rajda; Krisztina Bencsik; József Toldi; László Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2012-01-19       Impact factor: 3.575

7.  Altered serotonin uptake kinetics in multiple sclerosis.

Authors:  M Markianos; C Sfagos
Journal:  J Neurol       Date:  1988-03       Impact factor: 4.849

8.  Effect of fluoxetine on disease progression in a mouse model of ALS.

Authors:  J E Koschnitzky; K A Quinlan; T J Lukas; E Kajtaz; E J Kocevar; W F Mayers; T Siddique; C J Heckman
Journal:  J Neurophysiol       Date:  2014-03-05       Impact factor: 2.714

Review 9.  TDO as a therapeutic target in brain diseases.

Authors:  Cheng-Peng Yu; Ze-Zheng Pan; Da-Ya Luo
Journal:  Metab Brain Dis       Date:  2016-04-13       Impact factor: 3.584

Review 10.  Immunoregulatory molecules are master regulators of inflammation during the immune response.

Authors:  Hortensia de la Fuente; Danay Cibrián; Francisco Sánchez-Madrid
Journal:  FEBS Lett       Date:  2012-07-20       Impact factor: 4.124
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.